Summary
Agilent Technologies, Inc. reported solid revenue growth for the three and six months ended April 30, 2016, with total net revenue increasing by 6% and 3% respectively, year-over-year. This growth was driven by strong performance across its business segments, particularly Agilent CrossLab and Diagnostics and Genomics, with Life Sciences and Applied Markets showing moderate improvement. The company demonstrated improved profitability, with gross margins increasing by 2 percentage points and operating margins by 2 and 3 percentage points for the three and six-month periods, respectively. This margin expansion was attributed to factors like exiting the NMR business, improved logistics, and a pension curtailment gain. Financially, Agilent maintained a strong liquidity position with $2,139 million in cash and cash equivalents. The company continued to return capital to shareholders through dividends and share repurchases, demonstrating confidence in its ongoing cash flow generation. Significant investments were made in acquisitions, including Seahorse Bioscience, and strategic equity investments, such as Lasergen, indicating a focus on future growth and innovation. Despite some unfavorable foreign currency impacts, the company expressed optimism for continued growth, focusing on operating margin expansion and strategic investments.
Financial Highlights
57 data points| Revenue | $1.02B |
| Cost of Revenue | $489.00M |
| Gross Profit | $530.00M |
| R&D Expenses | $81.00M |
| SG&A Expenses | $318.00M |
| Operating Expenses | $888.00M |
| Operating Income | $131.00M |
| Interest Expense | $18.00M |
| Net Income | $91.00M |
| EPS (Basic) | $0.28 |
| EPS (Diluted) | $0.28 |
| Shares Outstanding (Basic) | 326.00M |
| Shares Outstanding (Diluted) | 328.00M |
Key Highlights
- 1Total net revenue increased by 6% to $1,019 million for the three months ended April 30, 2016, and by 3% to $2,047 million for the six months ended April 30, 2016.
- 2Gross margin improved by 2 percentage points to 52.0% for the three months and by 2 percentage points to 52.1% for the six months ended April 30, 2016.
- 3Operating margin increased by 2 percentage points to 12.9% for the three months and by 3 percentage points to 14.0% for the six months ended April 30, 2016.
- 4Net income from continuing operations was $91 million for the three months and $214 million for the six months ended April 30, 2016.
- 5Cash flow from operations was strong, providing $360 million for the six months ended April 30, 2016.
- 6The company completed the acquisition of Seahorse Bioscience for $242 million and made a strategic investment in Lasergen for $80 million.
- 7Agilent returned capital to shareholders through $75 million in dividend payments and approximately $196 million in share repurchases during the six months ended April 30, 2016.